Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on the shares. The firm highlights 2025 catalysts, including Merck’s (MRK) anti-tau Phase 1 data in mid-2025 with read-thrus to VY7523 given similar epitopes, and Voyager’s ALPL preclinical data later in 2025, which could inform differentiation vs. TfR brain shuttle.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics Reports 2024 Financial Results and Progress
- Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating
- Closing Bell Movers: Stitch Fix jumps over 20% on earnings beat, guidance raise
- Voyager Therapeutics reports Q4 EPS (59c), consensus (35c)
- Is VYGR a Buy, Before Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue